PET and PET–CT in Esophageal and Gastric Cancer

Methods in Molecular Biology

Volumn 727, Issue , 2011, Pages 59-76

  Wieder, Hinrich A ^a   Krause, Bernd J ^a   Herrmann, Ken ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Esophageal cancer; PET CT; Recurrence; Staging; Therapy monitoring

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ESOPHAGUS TUMOR; HUMAN; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; STOMACH TUMOR; TUMOR RECURRENCE;

ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 79956294307     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-062-1_5     Document Type: Chapter

References (40)

1. Flamen, P., Lerut, A., Van Cutsem, E., et al. (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18, 3202–10.
2. Heeren, P.A., Jager, P.L., Bongaerts, F., van Dullemen, H., Sluiter, W., Plukker, J.T. (2004) Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 45, 980–7.
3. Kato, H., Kuwano, H., Nakajima, M., et al. (2002) Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184, 279–83.
4. Kim, K., Park, S.J., Kim, B.T., Lee, K.S., Shim, Y.M. (2001) Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg 71, 290–4.
5. McAteer, D., Wallis, F., Couper, G., et al. (1999) Evaluation of F-18 FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 72, 525–9.
6. Meltzer, C.C., Luketich, J.D., Friedman, D., et al. (2000) Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 25, 882–7.
7. Yoon, Y.C., Lee, K.S., Shim, Y.M., Kim, B.T., Kim, K., Kim, T.S. (2003) Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology 227, 764–70.
8. Rasanen, J.V., Sihvo, E.I., Knuuti, M.J., et al. (2003) Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 10, 954–60.
9. Herrmann, K., Ott, K., Buck, A.K., et al. (2007) Imaging gastric cancer with PET and the radiotracers 18F-FLT and F-18 FDG: A comparative analysis. J Nucl Med 48, 1945–50.
10. van Westreenen, H.L., Westerterp, M., Bossuyt, P.M., et al. (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22, 3805–12.
11. Choi, J.Y., Lee, K.H., Shim, Y.M., et al. (2000) Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 41, 808–15.
12. Lerut, T., Flamen, P., Ectors, N., et al. (2000) Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 232, 743–52.
13. Yuan, S., Yu, Y., Chao, K.S., et al. (2006) Additional value of PET-CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 47, 1255–9.
14. Kim, S.K., Kang, K.W., Lee, J.S., et al. (2006) Assessment of lymph node metastases using F-18 FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 33, 148–55.
15. Kato, H., Miyazaki, T., Nakajima, M., Fukuchi, M., Manda, R., Kuwano, H. (2004) Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 91, 1004–9.
16. Flamen, P., Lerut, A., Van Cutsem, E., et al. (2000) The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120, 1085–92.
17. De Potter, T., Flamen, P., Van Cutsem, E., et al. (2002) Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 29, 525–9.
18. Park, M.J., Lee, W.J., Lim, H.K., Park, K.W., Choi, J.Y., Kim, B.T. (2009) Detecting recurrence of gastric cancer: The value of FDG PET-CT. Abdom Imaging 34, 441–7.
19. Mandard, A.M., Dalibard, F., Mandard, J.C., et al. (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma clinicopathologic correlations. Cancer 73, 2680–6.
20. Weber, W.A., Ott, K., Becker, K., et al. (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19, 3058–65.
21. Wieder, H.A., Brucher, B.L., Zimmermann, F., et al. (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22, 900–8.
22. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92, 205–16.
23. Buyse, M., Piedbois, Y., Piedbois, P., Gray, R. (2000) Tumour site, sex, and survival in colorectal cancer. Lancet 356, 858.
24. Bruzzi, P., Del Mastro, L., Sormani, M.P., et al. (2005) Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 23, 5117–25.
25. Goffin, J., Baral, S., Tu, D., Nomikos, D., Seymour, L. (2005) Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res 11, 5928–34.
26. Ratain, M.J. (2005) Phase II oncology trials: Let’s be positive. Clin Cancer Res 11, 5661–2.
27. Weber, W.A., Ziegler, S.I., Thodtmann, R., Hanauske, A.R., Schwaiger, M. (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40, 1771–7.
28. Westerterp, M., van Westreenen, H.L., Reitsma, J.B., et al. (2005) Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy – systematic review. Radiology 236, 841–51.
29. Brucher, B.L., Weber, W., Bauer, M., et al. (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography. Ann Surg 233, 300–9.
30. Flamen, P., Van Cutsem, E., Lerut, A., et al. (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced esophageal cancer. Ann Oncol 13, 361–8.
31. Port, J.L., Lee, P.C., Korst, R.J., et al. (2007) Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg 84, 393–400; discussion.
32. Swisher, S.G., Maish, M., Erasmus, J.J., et al. (2004) Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78, 1152–60; discussion 60.
33. Smithers, B.M., Couper, G.C., Thomas, J.M., et al. (2008) Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus 21, 151–8.
34. Lordick, F., Ruers, T., Aust, D.E., et al. (2008) European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 44, 1807–19.
35. Westerterp, M., Sloof, G.W., Hoekstra, O.S., et al. (2008) 18FDG uptake in oesophageal adenocarcinoma: Linking biology and outcome. J Cancer Res Clin Oncol 134, 227–36.
36. Siewert, J.R., Stein, H.J., Sendler, A., Fink, U. (1999) Surgical resection for cancer of the cardia. Semin Surg Oncol 17, 125–31.
37. Ott, K., Weber, W.A., Lordick, F., et al. (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24, 4692–8.
38. Lordick, F., Ott, K., Krause, B.J., et al. (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 8, 797–805.
39. Ott, K., Herrmann, K., Lordick, F., et al. (2008) Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: Long-term results of a prospective study. Clin Cancer Res 14, 2012–8.
40. Shah, M.A., Yeung, H.W., Coit, D., Trocola, R., Ilson, D., Randazzo, J. (2007) A phase II study of preoperative chemotherapy with irinotecan (CPT) and cisplatin (CIS) for gastric cancer (NCI 5917): FDG-PET-CT predicts patient outcome. J Clin Oncol 25, 18S.